Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and there is a clinical need for biomarkers which can identify chemotherapy respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hale, Matthew D., Nankivell, Matthew, Hutchins, Gordon G., Stenning, Sally P., Langley, Ruth E., Mueller, Wolfram, West, Nicholas P., Wright, Alexander I., Treanor, Darren, Hewitt, Lindsay C., Allum, William H., Cunningham, David, Hayden, Jeremy D., Grabsch, Heike I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363605/
https://www.ncbi.nlm.nih.gov/pubmed/27769054
http://dx.doi.org/10.18632/oncotarget.12723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363605/
https://www.ncbi.nlm.nih.gov/pubmed/27769054
http://dx.doi.org/10.18632/oncotarget.12723

Ejemplares similares